Thalidomide in the treatment of relapsed and refractory myeloma.

被引：0
|
作者：
Rajkumar, SV [1 ]
Fonseca, R [1 ]
Dispenzieri, A [1 ]
Lacy, MQ [1 ]
Witzig, TE [1 ]
Lust, JA [1 ]
Kyle, RA [1 ]
Gertz, MA [1 ]
Greipp, PR [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1414
引用
收藏
页码：316A / 316A
页数：1
相关论文
共 50 条
  • [1] Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma.
    Palumbo, A
    Giaccone, L
    Bertola, A
    Bringhen, S
    Rus, C
    Triolo, S
    Pileri, A
    Boccadoro, M
    BLOOD, 2000, 96 (11) : 292B - 292B
  • [2] Thalidomide plus melphalan in relapsed-refractory multiple myeloma.
    Offidani, M
    Mele, A
    Marconi, M
    Corvatta, L
    Candela, M
    Pieroni, S
    Malerba, L
    Rupoli, S
    Olivieri, A
    Leoni, P
    BLOOD, 2001, 98 (11) : 311B - 311B
  • [3] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [4] Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.
    Tosi, P
    Ronconi, S
    Zamagni, E
    Cellini, C
    Tura, S
    Cavo, M
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [5] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study.
    Hovenga, S
    Daenen, SMGJ
    de Wolf, JTM
    van Imhoff, GW
    Kluin-Nelemans, HC
    Vellenga, E
    BLOOD, 2003, 102 (11) : 686A - 686A
  • [6] Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma.
    Caravita, T
    Siniscalchi, A
    Niscola, P
    Santinelli, S
    Buccisano, F
    Montanaro, M
    De Fabritiis, P
    Amadori, S
    BLOOD, 2003, 102 (11) : 382B - 383B
  • [7] Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal, S
    Mehta, J
    Desikan, R
    Ayers, D
    Roberson, P
    Eddlemon, P
    Munshi, N
    Anaissie, E
    Wilson, C
    Dhodapkar, M
    Zeldis, J
    Barlogie, B
    Siegel, D
    Crowley, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21): : 1565 - 1571
  • [8] Thalidomide and dexamethasone combination for refractory multiple myeloma.
    Galani, E
    Grigoraki, V
    Kiamouris, C
    Samantas, E
    Economou, O
    Papdimitriou, C
    Gika, D
    Anagnostopoulos, N
    Dimopoulos, M
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [9] Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma.
    Somlo, G
    Bellamy, W
    Zimmerman, TM
    Frankel, P
    Tuscano, J
    O'Donnell, M
    Mohrbacher, A
    Forman, S
    Chen, H
    Doroshow, J
    Gandara, D
    BLOOD, 2005, 106 (11) : 723A - 723A
  • [10] Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma.
    Di Raimondo, F
    Pennisi, A
    Buglio, D
    Fiumara, P
    Palumbo, GA
    Giustolisi, R
    BLOOD, 2003, 102 (11) : 385B - 385B
12345